



The Importance of Education and Follow Up of Patients Under Direct Oral Anticoagulants. The Role of Anticoagulation Clinics



Juan Ramon de Moya Romero^{1,2*} and Edelmira Marti Saez³

¹MSN, Nursing Department, Podology and Nursing School, University of Valencia, Spain

²Anticoagulation Clinic in Hospital de Manises, Avd/Generalitat Valenciana n50, Manises, Valencia, Spain

³Phd. Hematologist, Hemostasis Department, HCUV, Hospital Clinico Universitario de Valencia, Spain

Submission: April 25, 2018; **Published:** May 01, 2018

***Corresponding author:** Juan Ramon de Moya Romero, MSN, Nursing Department, Podology and Nursing School, University of Valencia, Spain, Email: thenursemusician@gmail.com

Abstract

Since the emergence of Direct oral anticoagulants (DOACs), also known as Non vitamin K antagonists (NOACs), the management of these types of therapies has been expanded from anticoagulation clinics to other specialists and general practitioners, sometimes without experience in this field. It is true that these drugs don't need routine monitoring, but a close clinical vigilance is recommended, particularly as the target patient population tends to be elderly and frail. Important issues about DOACs management are

- a) Changes in dosification depending on renal function, age, weight or potential interactions
- b) education to patients and healthcare professionals
- c) patient's adherence to treatment and satisfaction

In our opinion Anticoagulation Clinics should be reference centers for better care and management of anti coagulated patients with VKA and DOACs and also places where unify clinical practices based in scientific evidence and current guidelines. Moreover, from a social point of view, these units can provide structured education to patients to improve treatment adherence and reduce complications.

Keywords: DOACs; NOACs; Anticoagulation Clinics; Education; Management; VKA; Adherence

Abbreviations: DOACs: Direct oral anticoagulants; NOACs: Non vitamin K antagonists; VKA: vitamin k antagonists

Introduction

Atrial fibrillation is the most common sustained arrhythmia in the general population and is associated with an increased risk of stroke [1-3]. For this reason, most of these patients will be treated with anticoagulant drugs for primary or secondary prophylaxis. Until the past decade the mainstay of this treatment was the vitamin k antagonists (VKA) or coumarins. Individual variability around VKA metabolism requires careful dose titration and patient education about drug-drug interactions and life style to minimize complications. To address these challenges, anticoagulation clinics were developed as multidisciplinary units to mitigate the risk of bleeding while ensuring safe and effective care for patients taking coumarins [4]. Since the emergence of Direct oral anticoagulants (DOACs), also known as Non vitamin K antagonists (NOACs), the management of these types of therapies has been expanded from anticoagulation clinics

to other specialists and general practitioners [5], sometimes without experience in this field.

In contrast to VKA, DOACs offer "rapid, predictable and stable anticoagulation intensity" [6]. Four DOACs have been approved to be used in Europe:

- a) Apixaban,
- b) Rivaroxaban,
- c) Edoxaban (direct factor Xa inhibitors) and
- d) Dabigatran (a direct thrombin inhibitor)

As they are not inferior to VKAs in efficacy and have a better security profile and easier management, some international guidelines have suggested to initiate anticoagulation therapy for AF or VTE with DOACs as the first option [7,8]. It is true that

these drugs don't need routine monitoring, but a close clinical vigilance is recommended, particularly as the target patient population tends to be elderly and frail [9,10]. Patient follow-up may be undertaken by professionals with experience. Growing evidence shows that nurse-coordinated AF clinics may be very helpful in this regard [11,12].

Important issues about DOACs management are:

- a. Changes in dosification depending on renal function, age, weight or potential interactions
- b. Education to patients and healthcare professionals, and 3. patient's adherence to treatment and satisfaction.

Some registries have shown that DOACs dosification in real life is not always correct [13]. Off-label doses of DOACs, especially under dosing, occur in more than 12% of patients. Patients with impaired renal function with a need of dose reduction that maintain the higher dose have more bleeding risk than those who are taking an adequate dose according to their creatinine clearance [14]. In the same way, those patients under dosed have higher stroke rates and need of hospitalization than those who are receiving a correct dose [15]. As renal function, weight or concomitant drugs may be variable, guidelines recommend to follow up these patients at least once or twice a year [9]. Continuous education to patients by a well trained team formed by nurses and physicians is a key issue. Multifaceted and customized educational intervention (including patients, caregivers and health providers) can improve the good use of oral anticoagulation in patients with atrial fibrillation and reduce the occurrence of stroke [16].

Expert anti coagulated patients showed higher rates of adherence and persistence with DOACs over naïve anti coagulated patients [17]. Some studies showed that DOACs' non-adherence reached 50% if no special measures are being taken [18]. Therefore, patient education may be essential to achieve a higher rate of adherence. Another important point is patients' preference. Expert anti coagulated patients had related in qualitative studies that prefer clinical monitorization of DOACs in Anticoagulation Clinics because they value specific experience and knowledge of physicians and nurses, assistance time and telephone support in questions about DOACs [19]. Studies about quality of life in anti coagulated patients show higher rates of satisfaction with specialist clinical management in anticoagulation compared with general primary attention [20].

Conclusion

In our opinion Anticoagulation Clinics should be reference centers for better care and management of anti coagulated patients with VKA and DOACs and also places where unify clinical practices based in scientific evidence and current guidelines. Moreover, from a social point of view, these units can provide structured education to patients to improve treatment adherence and reduce complications.

References

1. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, et al. (2012) Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. *Europace* 15(4): 486-493.
2. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 22(8): 983-988.
3. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, et al. (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. *Stroke* 36(6) : 1115-1119.
4. Martí S  ez E, Segado Torres A, Amat Mart  nez P, Remigia Pellicer MJ, P  rez Mart  nez A, et al. (2016) Prescripci  n y manejo de anticoagulantes orales de acci  n directa en pacientes con fibrilaci  n auricular fuera de una unidad de terapia anticoagulante. LVIII Congreso Nacional SEHH: 20, 21 y 22 October, Santiago de Compostela, Spain. Spanish Society of Hematology and Hemateraphy, Pp. 115.
5. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB (2016) Reimagining anticoagulation clinics in the era of direct oral anticoagulants. *Circulation: Cardiovascular Quality and Outcomes* 9(2): 182-185.
6. Kornej J, Potpara T, Lip GY (2013) Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. *Pol Arch Med Wewn* 123(11): 623-634
7. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, et al. (2017) Gu  a ESC 2016 sobre el diagn  stico y tratamiento de la fibrilaci  n auricular, desarrollada en colaboraci  n con la EACTS. *Revista Espa  ola de Cardiolog  a* 70(1): 50-51.
8. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, et al. (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest* 149(2): 315-352.
9. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, et al. (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *European heart journal* 39(16): 1330-1393.
10. De posicionamiento terap  utico (2016) Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevenci  n del ictus y la embolia sist  mica en pacientes con fibrilaci  n auricular no valvular. AEMPS.
11. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, et al. (2012) Nurse-led care vs usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. Routine clinical care in ambulatory patients with atrial fibrillation. *Eur Heart J* 33(21): 2692-2699.
12. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, et al. (2017) Integrated care in atrial fibrillation: a systematic review and meta-analysis. *Heart heartjnl* 103(24): 1947-1953.
13. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, et al. (2016) Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. *Journal of the American College of Cardiology* 68(24): 2597-2604.
14. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA (2017) Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. *Journal of the American College of Cardiology* 69(23): 2779-2790.
15. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, et al. (2017) Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation. *Journal of cardiovascular pharmacology* 69(2) : 118-129.

16. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, et al. (2017). A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. *The Lancet* 390(10104): 1737-1746.
17. Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA (2017) Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 37(10):1221-1230.
18. Rodriguez RA, Carrier M, Wells PS (2013) Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?. *Journal of Thrombosis and Haemostasis* 11(2): 390-394.
19. Bartoli Abdou JK, Patel JP, Crawshaw J, Vadher B, Brown A, et al. (2018) Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists-insights from the switching study. *Thrombosis research* 162: 62-68.
20. Baonza MY, Majada AC, García Borrás JF, González RS (2005) Calidad de vida de los pacientes tratados con anticoagulantes orales. *Atención Primaria* 36(4): 224-225.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/JPCR.2018.05.555666](https://doi.org/10.19080/JPCR.2018.05.555666)

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
<https://juniperpublishers.com/online-submission.php>